Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer
Daniel Sanghoon Shin, Kevin Park, Edward B. Garon, Steven M. Dubinett
Topics & Concepts
MedicinePembrolizumabNivolumabLung cancerEZH2Tumor microenvironmentCancerImmunotherapyImmune checkpointCancer researchBlockadeCancer immunotherapyPRC2ImmunologyOncologyEpigeneticsInternal medicineBiologyReceptorGeneBiochemistryEpigenetics and DNA MethylationCancer Immunotherapy and BiomarkersLung Cancer Research Studies